OpenEvidence, which has been called “ChatGPT for doctors,” is raising $250 million in equity financing at a $12 billion valuation, The Information reported.
The three-year-old company, which secured $200 million in October to be valued at $6 billion, generates annual recurring revenue of $150 million, according to the Dec. 12 story.
The startup also landed a $75 million series A funding round in early 2025 and partnered with the American College of Cardiology in November to accelerate the translation of research into clinical practice. Becker’s reached out to OpenEvidence for comment on the report.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.